Vineet Datta, Senior Director of Global Strategy at Datar Cancer Genetics Limited, shared on LinkedIn:
”Great to be in NewYork for a series of productive meetings. Our discussions including the recent USFDA 510(k) clearance for CellDx-Tissue reinforced the importance of strong scientific partnerships in advancing precision oncology, and in delivering innovative, clinically relevant cancer solutions that address real-world unmet needs.
Super to meet up with colleagues who share our commoncommitment to improving cancer care through science, smart genomics, and collaboration. We look forward to building on this momentum and deepening our collaborations in the months ahead.”
Other articles about precision oncology on OncoDaily.